ImmunityBio, Inc. Announced Full Year 2025 Earnings on March 3, 2026, Reporting "Full year net product revenue for ANKTIVA was $113 million"

ImmunityBio, Inc. reported full year net product revenue for ANKTIVA of $113 million, representing a 700% year-over-year increase compared to $14.1 million in 2024. In the fourth quarter, net product revenue increased from $31.1 million to $38.3 million.

Full year research and development expenses were $218.6 million, and selling, general, and administrative expenses decreased to $150 million.

Full year net loss attributable to ImmunityBio common stockholders was $351.4 million.

The company reported consolidated cash, cash equivalent, and marketable securities of $242.8 million as of December 31, 2025.

The company highlighted the commercial momentum of ANKTIVA, which is now authorized across 33 countries.

Management introduced askIB, an internally developed artificial intelligence solution utilizing advanced large language models to integrate with the global enterprise application suite.

The company also discussed the NANT Leonardo platform for automated cellular manufacturing using artificial intelligence and machine vision.

The company stated it will not be providing forward financial guidance on the call.

However, management intends to submit a biologics licensing application for the BCG-naive indication in the fourth quarter of 2026.

ImmunityBio partnered with Accord Healthcare to support commercial launch across 31 countries in Europe, including the United Kingdom and all 27 European Union member states.

The company also announced partnerships with Biopharma and Cigalah to expand access across the Middle East and North Africa region following the Saudi FDA approvals of ANKTIVA for nonmuscle-invasive bladder cancer and metastatic nonsmall cell lung cancer.